Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 143 No. 3738 (2013)

Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland

  • David Gasche
  • Tanja Ulle
  • Bernhard Meier
  • Roger-Axel Greiner
DOI
https://doi.org/10.4414/smw.2013.13851
Cite this as:
Swiss Med Wkly. 2013;143:w13851
Published
08.09.2013

Summary

QUESTION UNDER STUDY: The aim of this study was to evaluate the cost-effectiveness of ticagrelor and generic clopidogrel as add-on therapy to acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS), from a Swiss perspective.

METHODS: Based on the PLATelet inhibition and patient Outcomes (PLATO) trial, one-year mean healthcare costs per patient treated with ticagrelor or generic clopidogrel were analysed from a payer perspective in 2011. A two-part decision-analytic model estimated treatment costs, quality-adjusted life years (QALYs), life years and the cost-effectiveness of ticagrelor and generic clopidogrel in patients with ACS up to a lifetime at a discount of 2.5% per annum. Sensitivity analyses were performed.

RESULTS: Over a patient’s lifetime, treatment with ticagrelor generates an additional 0.1694 QALYs and 0.1999 life years at a cost of CHF 260 compared with generic clopidogrel. This results in an Incremental Cost Effectiveness Ratio (ICER) of CHF 1,536 per QALY and CHF 1,301 per life year gained. Ticagrelor dominated generic clopidogrel over the five-year and one-year periods with treatment generating cost savings of CHF 224 and 372 while gaining 0.0461 and 0.0051 QALYs and moreover 0.0517 and 0.0062 life years, respectively. Univariate sensitivity analyses confirmed the dominant position of ticagrelor in the first five years and probabilistic sensitivity analyses showed a high probability of cost-effectiveness over a lifetime.

CONCLUSION: During the first five years after ACS, treatment with ticagrelor dominates generic clopidogrel in Switzerland. Over a patient’s lifetime, ticagrelor is highly cost-effective compared with generic clopidogrel, proven by ICERs significantly below commonly accepted willingness-to-pay thresholds.

References

  1. Wieser S, Rüthemann I, Boni S de, Eichler K, Pletscher M, Radovanovic D, et al. Cost of Acute Coronary Syndrome in Switzerland in 2008. Swiss Med Wkly. 2012;142:w13655.
  2. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598–660. 10.1093/eurheartj/ehm161.
  3. Campbell-Scherer DL, Green LA. ACC/AHA Guideline Update for the Management of ST-Segment Elevation Myocardial Infarction. Am Fam Physician. 2009;79(12):1080–6.
  4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054. 10.1093/eurheartj/ehr236.
  5. Wijns W, Kolh P, Danchin N, Di MC, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–55. 10.1093/eurheartj/ehq277.
  6. Wallentin L, Becker RC, Cannon CP, Emanuelsson H, Held C, Horrow J, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045–57. 10.1056/NEJMoa0904327.
  7. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619. 10.1093/eurheartj/ehs215.
  8. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Appendix: Supplementary material. Eur Heart J. 2012.
  9. Federal Office of Public Health. Krankenversicherungsprämien-Index. Neuchâtel 2011.
  10. Federal Office of Public Health. Spezialitätenliste. Bern 2011.
  11. Federal Office of Public Health. TARMED. Neuchâtel 2012.
  12. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2006;45(4):203–20.
  13. tarifsuisse ag. Personal communication of Tarifsuisse; 2011.
  14. Winterthur Insitute of Health Economics. Cost survey acute coronary syndrome (ACS); 2011.
  15. Carrel T. Heutiger Stand der Herztransplantation und der mechanischen Kreislaufunterstützung. BioFokus Spezial 2010;20.
  16. Blood Transfusion Service Zürich. Preisliste. Schlieren 2011.
  17. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013;34(3):220–8. 10.1093/eurheartj/ehs149.
  18. Allen LA, O’Donnell CJ, Camargo CA, Giugliano RP, Lloyd-Jones DM. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am Heart J. 2006;151(5):1065–71.
  19. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Five-Year Survival After First-Ever Stroke and Related Prognostic Factors in the Pearth Community Stroke Study. Stroke. 2000;31:2080–6.
  20. Taneja AK, Collinson J, Flather MD, Bakhai A, Arenaza DP de, Wang D, et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). European Heart Journal 2004;25(22):2013–8. 10.1016/j.ehj.2004.08.009.
  21. Federal Office of Statistics. Konsumentenpreis-Index für Gesundheit. Neuchâtel 2011.
  22. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation; 2006.
  23. Collet D. Modelling Survival Data in Medical Research, 2; 2003.
  24. Federal Office of Statistics. STAT-TAB: Die interaktive Statistikdatenbank. Neuchâtel 2010.
  25. Federal Office of Statistics. Sterbefälle und Sterbeziffern. Neuchâtel 2012.
  26. Brändle M, Goodallb G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglotazon in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly. 2009;139(11-12):173–84.
  27. Schwenkglenks M, Brazier JE, Szucs TD, Fox KA. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011;14(1):24–33. 10.1016/j.jval.2010.10.025.
  28. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366(9489):921–9. 10.1016/S0140-6736(05)67221-2.
  29. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–44.
  30. Henriksson M, Janzon M. Cost-effectiveness of ticagrelor in acute coronary syndromes. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):9–18. 10.1586/erp.12.89.
  31. Theidel U, Asseburg C, Giannitsis E, Katus H. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol. 2013. 10.1007/s00392-013-0552-7.
  32. Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health. 2011;14(4):483–91. 10.1016/j.jval.2010.11.012.
  33. Aurbach A, Russ W, Battegay E, Bucher HC, Brecht JG, Schadlich PK, et al. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective. Swiss Med Wkly. 2004;134(27-28):399–405.
  34. Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet. 2007;370(9598):1552–9. 10.1016/S0140-6736(07)61660-2.
  35. Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction – an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther. 2006;20(3):193–204. 10.1007/s10557-006-8282-y.
  36. TARMED Suisse. TARMED Tarifbrowser. Bern 2012.

Most read articles by the same author(s)